Table 2.
Oncological results in the study cohort according to the degree of metastasis.
| Group A | Group B | p value | |
|---|---|---|---|
| Median follow-up (mo) | 40 (27–53) | 39 (31–54) | 0.263 |
| All patients | 54 | 54 | |
| Median PSA nadir, ng/mL | 0.025 (0.003–0.273) | 0.230 (0.051–1.035) | 0.001 |
| Median FFS (mo) | 39.0 ± 5.79 | 21.0 ± 5.13 | 0.005 |
| Median time to mCRPC (mo) | 39.0 ± 7.22 | 21.0 ± 5.71 | 0.007 |
| Median CSS (mo) | NR | 75.0 ± 6.50 | 0.849 |
| Median OS (mo) | NR | 67.0 ± 12.18 | 0.851 |
| Deaths from PCa | 15 (27.8%) | 20 (37.0%) | 0.304 |
| Deaths from all causes | 20 (37.0%) | 23 (42.6%) | 0.555 |
| Low metastatic burden patients | 25 | 24 | |
| Median PSA nadir, ng/mL | 0.030 (0.003–0.222) | 0.173 (0.041–1.001) | 0.037 |
| Median FFS (mo) | NR | 28.0 ± 15.90 | 0.190 |
| Time to mCRPC(mo) | NR | 26.0 ± 14.98 | 0.195 |
| Median CSS (mo) | 60.0 ± 10.00 | NR | 0.280 |
| Median OS (mo) | 54.0 ± 5.72 | NR | 0.144 |
| Deaths from PCa | 7 (28.0%) | 4 (16.7%) | 0.342 |
| Deaths from all causes | 10 (40.0%) | 5 (20.8%) | 0.146 |
| High metastatic burden patients | 29 | 30 | |
| Median PSA nadir, ng/mL | 0.020 (0.003–0.459) | 0.258 (0.079–1.035) | 0.012 |
| Median FFS (mo) | 46.0 ± 10.24 | 18.0 ± 6.16 | 0.010 |
| Time to mCRPC(mo) | 44.0 ± 8.53 | 15.0 ± 6.16 | 0.011 |
| Median CSS (mo) | NR | 66.0 ± 9.78 | 0.434 |
| Median OS (mo) | NR | 52.0 ± 14.98 | 0.488 |
| Deaths from PCa | 8 (27.6%) | 16 (53.3%) | 0.044 |
| Deaths from all causes | 10 (34.5%) | 18 (60.0%) | 0.050 |
Group A, cryoablation + ADT. Group B, ADT alone.
ADT androgen deprivation therapy, mo months, PSA prostate-specific antigen, FFS failure-free survival, mCRPC metastatic castration-resistant prostate cancer, CSS cancer-specific survival, OS overall survival, PCa prostate cancer, NR not reached.